Imugene Stock Forecast for 2023 - 2025 - 2030

Updated on 03/28/2024

Stock Rating
4
Price Target
$0.42
Consensus
Outperform
Upside
281.82%
Analysts
0
Stock Rating
4
Upside
281.82%
Analysts
0
Price Target
$0.42

Imugene Stock Forecast and Price Target

Based on the current earnings figures, this year's price targets for Imugene were recently set by distinguished experts, with an average mark of $0.42. If it reached this goal, it would represent a potential upside of approximately 281.82% from the previous closing price in March, 2024. The high end is $0.49, and the low is $0.10. If you are interested in IMU stock, it is important to also consider its competitors.

$0.42

281.82% Upside

Buy
Buy

Imugene Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Imugene's Price has grown by 100.00%, rising from $-0.00 to $0.00. For the next year, analysts predict that Fair Value will reach $0.11 – an increase of 100.00%. Over the next seven years, experts believe that Imugene's Fair Value will grow at a rate of 100.00%.

2024 Fair Value Forecast
$0.11
2025 Fair Value Forecast
$0.12
2026 Fair Value Forecast
$0.13
2027 Fair Value Forecast
$0.15
2028 Fair Value Forecast
$0.16
2029 Fair Value Forecast
$0.18
2030 Fair Value Forecast
$0.19
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CSL Stock Forecast CSL Outperform 12
$281.20 Buy/Sell $205.51 -27.94%
TLX Stock Forecast Telix Pharmaceuticals Buy 6
$11.29 Buy/Sell $13.37 24.00%
NEU Stock Forecast Neuren Pharmaceuticals Buy 11
$20.07 Buy/Sell $26.43 32.44%
PNV Stock Forecast PolyNovo Outperform 8
$2.40 Buy/Sell $1.88 -10.83%
CUV Stock Forecast Clinuvel Pharmaceuticals Buy 16
$13.21 Buy/Sell $27.41 67.68%

Imugene Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Imugene's Revenue has grown by 185.23%, rising from $4.13M to $11.78M. According to 2 analysts, Imugene's Revenue will fall by 100.00% in the next year, reaching $0.00. Over the next eight years, experts believe that Imugene's Revenue will grow at a rate of 10278.10%.

2024 Rev Forecast
$0.00
2025 Rev Forecast
$0.00
2026 Rev Forecast
$0.08B
2027 Rev Forecast
$0.31B
2027 Rev Forecast
$0.31B
2028 Rev Forecast
$0.62B
2029 Rev Forecast
$0.95B
2030 Rev Forecast
$1.22B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IMM Stock Forecast Immutep Buy 8
$0.40 Buy/Sell $1.26 137.50%
MSB Stock Forecast Mesoblast Buy 9
$0.32 Buy/Sell $0.69 100.00%
PYC Stock Forecast PYC Therapeutics Buy 8
$0.08 Buy/Sell $0.30 337.50%

Imugene Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BOT Stock Forecast Botanix Pharmaceuticals - 0
$0.19 Buy/Sell $0.00 -100.00%
CGS Stock Forecast Cogstate Outperform 11
$1.22 Buy/Sell $1.85 39.34%
DXB Stock Forecast Dimerix - 0
$0.30 Buy/Sell $0.00 -100.00%

Imugene Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$-41000000.00
2025 FCF Forecast
$-42500000.00
2026 FCF Forecast
$-21900000.00
2027 FCF Forecast
$-35375070.00
2028 FCF Forecast
$-41558632.24
2029 FCF Forecast
$-47250779.56
2030 FCF Forecast
$-37009960.61
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ACW Stock Forecast Actinogen Medical 5
$0.03 Buy/Sell $0.15 -100.00%
BIT Stock Forecast Biotron - 0
$0.07 Buy/Sell $0.00 -100.00%
SPL Stock Forecast Starpharma Holdings - 8
$0.13 Buy/Sell $0.95 -100.00%

Imugene EBITDA Forecast for 2023 - 2025 - 2030

Imugene's EBITDA has seen growth In the last three years, going from $-10.72M to $-37.26M – a gain of 247.57% In the next year, analysts believe that EBITDA will reach $-62.16M – an increase of 66.83%. For the next seven years, the forecast is forEBITDA to grow by 65.66%.

2024 EBITDA Forecast
$-62160000.00
2025 EBITDA Forecast
$-74430000.00
2026 EBITDA Forecast
$-59248761.00
2027 EBITDA Forecast
$-53140213.74
2028 EBITDA Forecast
$-56794489.11
2029 EBITDA Forecast
$-62604565.34
2030 EBITDA Forecast
$-61726014.61
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IVX Stock Forecast Invion - 0
$0.01 Buy/Sell $0.00 -100.00%
PTX Stock Forecast Prescient Therapeutics - 2
$0.05 Buy/Sell $0.20 -100.00%
CYP Stock Forecast Cynata Therapeutics 0
$0.19 Buy/Sell $1.24 552.63%

Imugene EBIT Forecast for 2023 - 2025 - 2030

In the last three years, EBIT for Imugene has grown by 267.63%, going from $-10.75M to $-39.52M. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $-57.28M – an increase of 44.94%. According to professionals, by 2030, Imugene's EBIT will have decreased by 2975.15%, falling down to $1.14B.

2024 EBIT Forecast
$-57280000.00
2025 EBIT Forecast
$-65130000.00
2026 EBIT Forecast
$-17160000.00
2027 EBIT Forecast
$0.23B
2028 EBIT Forecast
$0.54B
2029 EBIT Forecast
$0.87B
2030 EBIT Forecast
$1.14B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
1AI Stock Forecast Algorae Pharmaceuticals - -4
$0.01 Buy/Sell $0.00 -100.00%
IMC Stock Forecast Immuron - 0
$0.07 Buy/Sell $0.00 -100.00%
ATH Stock Forecast Alterity Therapeutics - 0
$0.00 Buy/Sell $0.75 0.00%

Imugene EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Imugene's EPS has grown by 100.00%, rising from $-0.00 to $0.00. For the next year, analysts predict that EPS will reach $-0.01 – an increase of 100.00%. Over the next seven years, experts believe that Imugene's EPS will grow at a rate of 100.00%.

2024 EPS Forecast
$-0.01
2025 EPS Forecast
$-0.01
2026 EPS Forecast
$0.00
2027 EPS Forecast
$0.02
2028 EPS Forecast
$0.04
2029 EPS Forecast
$0.06
2030 EPS Forecast
$0.07
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
OSL Stock Forecast OncoSil Medical - 0
$0.01 Buy/Sell $0.11 -100.00%
GTG Stock Forecast Genetic Technologies 0
$0.15 Buy/Sell $1.00 566.67%
BNOX Stock Forecast Bionomics Outperform -13
$1.13 Buy/Sell $18.04 1279.65%